ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for URGN

Stock NameUroGen Pharma Ltd
TickerURGN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINIL0011407140

Show aggregate URGN holdings

News associated with URGN

Urogen Pharma (NASDAQ:URGN) Trading Down 8% After Insider Selling
Urogen Pharma (NASDAQ:URGN – Get Free Report) traded down 8% on Wednesday following insider selling activity. The stock traded as low as $19.25 and last traded at $19.04. 265,793 shares were traded during mid-day trading, a decline of 83% from the average session volume of 1,523,562 shares. The stock had previously closed at $20.69. Specifically, […] - 2025-09-12 02:22:45
Urogen Pharma (NASDAQ:URGN) Receives $32.00 Consensus PT from Analysts
Urogen Pharma (NASDAQ:URGN – Get Free Report) has earned a consensus rating of “Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The […] - 2025-09-10 02:33:00
XTX Topco Ltd Raises Position in Urogen Pharma (NASDAQ:URGN)
XTX Topco Ltd grew its holdings in shares of Urogen Pharma (NASDAQ:URGN – Free Report) by 39.3% in the 1st quarter, HoldingsChannel.com reports. The firm owned 25,967 shares of the company’s stock after purchasing an additional 7,326 shares during the quarter. XTX Topco Ltd’s holdings in Urogen Pharma were worth $287,000 as of its most […] - 2025-08-11 05:44:58
Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% After Earnings Miss
Urogen Pharma (NASDAQ:URGN – Get Free Report)’s stock price dropped 14.4% during trading on Thursday following a dissappointing earnings announcement. The stock traded as low as $18.59 and last traded at $17.12. Approximately 366,073 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 1,583,408 shares. The stock had […] - 2025-08-08 04:46:54
Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from D. Boral Capital
Urogen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $25.00 target price on the stock. D. Boral Capital’s price target points to a potential upside of 24.94% from the stock’s previous close. […] - 2025-08-07 03:14:58
Urogen Pharma (NASDAQ:URGN) Receives $32.86 Consensus PT from Analysts
Urogen Pharma (NASDAQ:URGN – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-07-22 02:25:21
UroGen Pharma Announces Data Of Phase 2b Of Bladder Cancer Study
(RTTNews) - UroGen Pharma Ltd. (URGN), Monday announced results of a five-year long-term extension study of the Phase 2b OPTIMA II trial, evaluating ZUSDURI for intravesical solution in patients with low-grade intermediate-risk non-muscle invasive bladder cancer. - 2025-07-21 10:42:58
Alps Advisors Inc. Reduces Holdings in Urogen Pharma (NASDAQ:URGN)
Alps Advisors Inc. reduced its stake in shares of Urogen Pharma (NASDAQ:URGN – Free Report) by 4.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,762 shares of the company’s stock after selling 1,359 shares during the period. Alps Advisors Inc. owned […] - 2025-07-16 05:23:13
Brokerages Set Urogen Pharma (NASDAQ:URGN) PT at $32.86
Urogen Pharma (NASDAQ:URGN – Get Free Report) has earned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The […] - 2025-06-27 02:37:05
Urogen Pharma (NASDAQ:URGN) Short Interest Down 29.9% in May
Urogen Pharma (NASDAQ:URGN – Get Free Report) was the recipient of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 3,920,000 shares, a drop of 29.9% from the May 15th total of 5,590,000 shares. Based on an average daily volume of 1,670,000 shares, the […] - 2025-06-19 02:54:55
Urogen Pharma (NASDAQ:URGN) Sees Strong Trading Volume After Analyst Upgrade
Shares of Urogen Pharma (NASDAQ:URGN – Get Free Report) saw unusually-high trading volume on Monday after HC Wainwright upgraded the stock from a neutral rating to a buy rating. HC Wainwright now has a $50.00 price target on the stock. Approximately 2,166,518 shares were traded during trading, an increase of 119% from the previous session’s […] - 2025-06-18 02:10:51
UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Scotiabank Analyst Says
UroGen Pharma (NASDAQ:URGN – Free Report) had its price target hoisted by Scotiabank from $23.00 to $47.00 in a research note issued to investors on Friday morning,Benzinga reports. Scotiabank currently has a sector outperform rating on the stock. Several other equities analysts have also issued reports on the company. D. Boral Capital reiterated a “buy” […] - 2025-06-16 02:30:47
UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Guggenheim Analyst Says
UroGen Pharma (NASDAQ:URGN – Free Report) had its price target upped by Guggenheim from $15.00 to $30.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other equities research analysts have also recently commented on URGN. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma […] - 2025-06-16 02:30:47
Two Sigma Investments LP Sells 30,139 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)
Two Sigma Investments LP trimmed its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 34.6% in the 4th quarter, Holdings Channel reports. The firm owned 56,895 shares of the company’s stock after selling 30,139 shares during the quarter. Two Sigma Investments LP’s holdings in UroGen Pharma were worth $606,000 at the […] - 2025-06-09 04:56:44
UroGen Pharma (NASDAQ:URGN) Given New $10.00 Price Target at Oppenheimer
UroGen Pharma (NASDAQ:URGN – Get Free Report) had its price objective cut by Oppenheimer from $36.00 to $10.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 103.25% from the company’s previous close. A number of other […] - 2025-06-05 02:16:56
Ameriprise Financial Inc. Has $523,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)
Ameriprise Financial Inc. lifted its holdings in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 9.3% during the 4th quarter, HoldingsChannel reports. The fund owned 49,153 shares of the company’s stock after acquiring an additional 4,188 shares during the quarter. Ameriprise Financial Inc.’s holdings in UroGen Pharma were worth $523,000 as of its most recent […] - 2025-06-04 05:48:46
Biotech Stocks Facing FDA Decision In June 2025
(RTTNews) - As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. From January through May 2025, the U.S. regulatory agency has approved 13 novel drugs, a modest decline from the 16 approvals recorded during the same period in 2024. - 2025-05-30 06:02:12
UroGen Pharma Ltd. (NASDAQ:URGN) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy […] - 2025-05-30 02:10:58
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by Balyasny Asset Management L.P.
Balyasny Asset Management L.P. cut its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 14.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,481 shares of the company’s stock after selling 4,131 shares during the period. Balyasny […] - 2025-05-18 05:45:17
UroGen Pharma (NASDAQ:URGN) Earns Buy Rating from HC Wainwright
UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $55.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 457.24% from the company’s previous close. URGN has been […] - 2025-05-15 02:48:49
UroGen Pharma (NASDAQ:URGN) Shares Gap Down on Disappointing Earnings
UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) shares gapped down before the market opened on Monday following a weaker than expected earnings announcement. The stock had previously closed at $10.38, but opened at $9.90. UroGen Pharma shares last traded at $11.19, with a volume of 402,553 shares trading hands. The company reported ($0.92) earnings […] - 2025-05-14 02:22:54
MetLife Investment Management LLC Buys 2,727 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)
MetLife Investment Management LLC increased its stake in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 13.6% during the fourth quarter, HoldingsChannel reports. The firm owned 22,766 shares of the company’s stock after acquiring an additional 2,727 shares during the period. MetLife Investment Management LLC’s holdings in UroGen Pharma were worth $242,000 as of its […] - 2025-05-08 05:02:47
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $32.86 Average PT from Analysts
Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have received an average rating of “Buy” from the eight brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. […] - 2025-05-08 02:52:55
Alliancebernstein L.P. Acquires 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)
Alliancebernstein L.P. grew its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 751.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 199,259 shares of the company’s stock after acquiring an additional 175,859 shares during the quarter. Alliancebernstein L.P.’s holdings in UroGen Pharma were worth $2,122,000 at the end […] - 2025-04-17 04:30:58
UroGen Pharma (NASDAQ:URGN) Price Target Cut to $55.00 by Analysts at HC Wainwright
UroGen Pharma (NASDAQ:URGN – Get Free Report) had its price target decreased by equities researchers at HC Wainwright from $64.00 to $55.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 408.32% from the stock’s previous close. […] - 2025-03-13 04:41:05
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital
D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report issued on Monday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock. Other research analysts have also issued reports about the company. LADENBURG THALM/SH SH started coverage on UroGen Pharma in […] - 2025-03-11 03:50:47
Oppenheimer & Co. Inc. Purchases Shares of 11,875 UroGen Pharma Ltd. (NASDAQ:URGN)
Oppenheimer & Co. Inc. acquired a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,875 shares of the company’s stock, valued at approximately $126,000. Several other […] - 2025-03-10 06:16:51
UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from HC Wainwright
UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $64.00 price objective on the stock. URGN has been the topic of several other reports. D. Boral Capital reiterated a […] - 2025-02-27 06:44:57
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital
D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock. UroGen Pharma Trading Down 1.9 % NASDAQ:URGN opened at $10.56 on Tuesday. The company has a debt-to-equity ratio of […] - 2025-02-19 04:56:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) URGN holdings

DateNumber of URGN Shares HeldBase Market Value of URGN SharesLocal Market Value of URGN SharesChange in URGN Shares HeldChange in URGN Base ValueCurrent Price per URGN Share HeldPrevious Price per URGN Share Held
2025-12-24 (Wednesday)31,146USD 740,029URGN holding increased by 11213USD 740,0290USD 11,213 USD 23.76 USD 23.4
2025-12-23 (Tuesday)31,146URGN holding decreased by -876USD 728,816URGN holding decreased by -26263USD 728,816-876USD -26,263 USD 23.4 USD 23.58
2025-12-22 (Monday)32,022USD 755,079URGN holding increased by 24977USD 755,0790USD 24,977 USD 23.58 USD 22.8
2025-12-19 (Friday)32,022URGN holding decreased by -2726USD 730,102URGN holding decreased by -24625USD 730,102-2,726USD -24,625 USD 22.8 USD 21.72
2025-12-18 (Thursday)34,748USD 754,727URGN holding decreased by -31273USD 754,7270USD -31,273 USD 21.72 USD 22.62
2025-12-17 (Wednesday)34,748URGN holding decreased by -400USD 786,000URGN holding decreased by -38924USD 786,000-400USD -38,924 USD 22.62 USD 23.47
2025-12-16 (Tuesday)35,148URGN holding decreased by -80USD 824,924URGN holding increased by 19964USD 824,924-80USD 19,964 USD 23.47 USD 22.85
2025-12-15 (Monday)35,228URGN holding increased by 160USD 804,960URGN holding increased by 40478USD 804,960160USD 40,478 USD 22.85 USD 21.8
2025-12-12 (Friday)35,068USD 764,482URGN holding decreased by -19638USD 764,4820USD -19,638 USD 21.8 USD 22.36
2025-12-11 (Thursday)35,068URGN holding increased by 164USD 784,120URGN holding increased by 9600USD 784,120164USD 9,600 USD 22.36 USD 22.19
2025-12-10 (Wednesday)34,904USD 774,520URGN holding decreased by -17801USD 774,5200USD -17,801 USD 22.19 USD 22.7
2025-12-09 (Tuesday)34,904USD 792,321URGN holding decreased by -13263USD 792,3210USD -13,263 USD 22.7 USD 23.08
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of URGN by Blackrock for IE00BYXG2H39

Show aggregate share trades of URGN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-12-23SELL-876 23.400* 14.18 Profit of 12,420 on sale
2025-12-19SELL-2,72623.20021.720 21.868USD -59,612 14.10 Loss of -21,179 on sale
2025-12-17SELL-40023.80022.420 22.558USD -9,023 14.03 Loss of -3,412 on sale
2025-12-16SELL-8024.71022.880 23.063USD -1,845 13.98 Loss of -726 on sale
2025-12-15BUY16022.92021.400 21.552USD 3,448 13.95
2025-12-11BUY16422.62021.740 21.828USD 3,580 13.87
2025-12-04BUY1,58024.91523.915 24.015USD 37,944 13.66
2025-12-02BUY1,18528.68524.000 24.468USD 28,995 13.56
2025-11-28BUY7929.46028.415 28.520USD 2,253 13.42
2025-11-26BUY23730.00027.170 27.453USD 6,506 13.26
2025-11-25BUY40027.98026.700 26.828USD 10,731 13.20
2025-11-24BUY8027.07025.890 26.008USD 2,081 13.13
2025-11-20SELL-31626.28024.701 24.859USD -7,855 13.01 Loss of -3,744 on sale
2025-11-19BUY7925.60023.250 23.485USD 1,855 12.95
2025-11-18BUY47424.08022.700 22.838USD 10,825 12.90
2025-11-17BUY15824.12023.360 23.436USD 3,703 12.85
2025-11-14BUY7925.00023.000 23.200USD 1,833 12.79
2025-11-12BUY7925.19023.520 23.687USD 1,871 12.67
2025-11-10BUY7924.89022.620 22.847USD 1,805 12.57
2025-11-07BUY7923.89521.750 21.965USD 1,735 12.51
2025-11-04BUY7920.58019.500 19.608USD 1,549 12.38
2025-10-30BUY40020.19819.170 19.273USD 7,709 12.26
2025-10-29BUY1,90419.78020.180 20.140USD 38,347 12.22
2025-10-22SELL-30017.66018.565 18.475USD -5,542 12.04 Loss of -1,932 on sale
2025-10-20BUY15017.99518.005 18.004USD 2,701 11.97
2025-10-17BUY37416.95017.180 17.157USD 6,417 11.94
2025-10-15BUY59217.29017.640 17.605USD 10,422 11.91
2025-10-03BUY52517.40017.655 17.630USD 9,255 11.86
2025-10-02BUY7517.07018.031 17.935USD 1,345 11.83
2025-09-30BUY15019.95020.030 20.022USD 3,003 11.75
2025-09-26BUY15018.34018.390 18.385USD 2,758 11.67
2025-09-25BUY15017.26017.990 17.917USD 2,688 11.63
2025-09-24SELL-1,61917.99018.450 18.404USD -29,796 11.60 Loss of -11,022 on sale
2025-09-18BUY8018.87018.930 18.924USD 1,514 11.55
2025-09-17BUY24318.10018.650 18.595USD 4,519 11.51
2025-08-20SELL-32019.31019.410 19.400USD -6,208 11.33 Loss of -2,582 on sale
2025-07-30BUY31619.22019.740 19.688USD 6,221 11.03
2025-07-17SELL-15815.41015.500 15.491USD -2,448 10.65 Loss of -765 on sale
2025-07-11SELL-64014.24014.640 14.600USD -9,344 10.55 Loss of -2,593 on sale
2025-07-07BUY24013.49013.940 13.895USD 3,335 10.46
2025-07-02BUY4,40012.96013.640 13.572USD 59,717 10.42
2025-06-20BUY2,10914.65015.610 15.514USD 32,719 10.38
2025-06-11BUY1507.3007.570 7.543USD 1,131 10.27
2025-06-10BUY1507.0507.460 7.419USD 1,113 10.30
2025-06-04SELL-754.9205.370 5.325USD -399 10.43 Profit of 383 on sale
2025-04-23BUY7410.20010.510 10.479USD 775 11.12
2025-04-10SELL-5849.3909.948 9.892USD -5,777 11.23 Profit of 780 on sale
2025-04-08SELL-739.66010.490 10.407USD -760 11.26 Profit of 62 on sale
2025-04-07SELL-739.96010.440 10.392USD -759 11.27 Profit of 64 on sale
2025-04-04SELL-37010.25010.520 10.493USD -3,882 11.29 Profit of 293 on sale
2025-04-01BUY2,33810.63011.320 11.251USD 26,305 11.30
2025-03-31SELL-20111.06011.158 11.148USD -2,241 11.30 Profit of 30 on sale
2025-03-14SELL-1,08811.07011.230 11.214USD -12,201 11.26 Profit of 45 on sale
2025-03-07SELL-1369.82010.427 10.366USD -1,410 11.32 Profit of 129 on sale
2025-03-04SELL-689.6009.660 9.654USD -656 11.38 Profit of 117 on sale
2025-02-25BUY1369.5109.810 9.780USD 1,330 11.55
2025-02-19SELL-6810.82011.090 11.063USD -752 11.64 Profit of 39 on sale
2025-02-13BUY20110.54010.650 10.639USD 2,138 11.72
2025-02-12BUY6710.37010.430 10.424USD 698 11.75
2025-02-11BUY26810.24010.760 10.708USD 2,870 11.78
2024-12-30SELL-2,60410.52010.910 10.871USD -28,308 12.20 Profit of 3,463 on sale
2024-11-18SELL-1,11011.04011.604 11.548USD -12,818 12.26 Profit of 790 on sale
2024-11-08SELL-7412.12012.300 12.282USD -909 12.26 Loss of -1 on sale
2024-10-21SELL-7512.52012.820 12.790USD -959 0.00 Loss of -959 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of URGN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19201,2700525,23538.3%
2025-09-18193,0130416,72446.3%
2025-09-17424,4970779,42854.5%
2025-09-16254,5740768,15733.1%
2025-09-15216,49210871,91824.8%
2025-09-12170,9770455,78137.5%
2025-09-1187,56110,207392,41722.3%
2025-09-10203,5095,692963,01421.1%
2025-09-09264,5672,083616,42142.9%
2025-09-08451,4132501,140,58539.6%
2025-09-05105,995100478,99322.1%
2025-09-04684,2811301,076,56563.6%
2025-09-03246,6680640,14138.5%
2025-09-02181,294600581,02131.2%
2025-08-29213,5790803,08126.6%
2025-08-28104,219200449,32923.2%
2025-08-27143,8860719,72320.0%
2025-08-26172,8115505,60434.2%
2025-08-25131,2190653,77320.1%
2025-08-22151,4310471,64832.1%
2025-08-21108,2890375,73928.8%
2025-08-20134,2960446,59130.1%
2025-08-19134,3321301,98544.5%
2025-08-1890,8200297,10530.6%
2025-08-15151,270200359,54442.1%
2025-08-14191,6610482,34739.7%
2025-08-13246,0830623,32939.5%
2025-08-12191,041647658,06829.0%
2025-08-1182,113863407,37820.2%
2025-08-08209,61115,174550,52238.1%
2025-08-07465,21323,405859,52354.1%
2025-08-06114,892379444,83625.8%
2025-08-05285,5410832,98334.3%
2025-08-04142,0081,012400,54135.5%
2025-08-01198,5210459,22843.2%
2025-07-31141,2330429,60232.9%
2025-07-30155,57221432,64136.0%
2025-07-29146,7991,642398,78336.8%
2025-07-28138,2401,111429,16232.2%
2025-07-25175,0945,854632,83727.7%
2025-07-24159,4031,322434,32436.7%
2025-07-23383,2703,1451,145,46333.5%
2025-07-22537,6213001,036,39951.9%
2025-07-21239,9830570,23142.1%
2025-07-18240,9501403,36659.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy